Calithera Biosciences Completes Patient Enrollment in Randomized Phase 2 ENTRATA Trial of Telaglenastat (CB-839) and Everolimus in Renal Cell Carcinoma
Calithera Biosciences, Inc. (CALA)
Last calithera biosciences, inc. earnings: 3/11 04:10 pm
Check Earnings Report
US:NASDAQ Investor Relations:
calithera.com
Company Research
Source: GlobeNewswire
SOUTH SAN FRANCISCO, Calif., Feb. 04, 2019 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that it has completed patient enrollment in the ongoing Phase 2 ENTRATA trial. ENTRATA is a randomized clinical study of the glutaminase inhibitor CB-839 combined with everolimus versus placebo with everolimus for the treatment of advanced renal cell carcinoma (RCC). CB-839 now has the International Nonproprietary Name (INN) telaglenastat, as recommended by the World Health Organization. “The ENTRATA trial is the first randomized trial evaluating the glutaminase inhibitor telaglenastat. There is ample evidence demonstrating the potential of glutaminase inhibition to block growth and survival of cancer cells,” said Susan Molineaux, PhD, President and Chief Executive Off
Show less
Read more
Impact Snapshot
Event Time:
CALA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CALA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CALA alerts
High impacting Calithera Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
CALA
News
- Calithera Biosciences, Inc. (NASDAQ: CALA) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Calithera Biosciences, Inc. (NASDAQ: CALA) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Calithera Biosciences, Inc. (NASDAQ: CALA) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Calithera Biosciences, Inc. (NASDAQ: CALA) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat
- Calithera Biosciences, Inc. (NASDAQ: CALA) is now covered by analysts at StockNews.com. They set a "hold" rating on the stock.MarketBeat